Therapeutic yoga reduces pro-tumorigenic cytokines in cancer survivors

Support Care Cancer. 2022 Dec 15;31(1):33. doi: 10.1007/s00520-022-07536-y.

Abstract

Introduction: Chronic inflammation can remain many years after the completion of cancer treatment and is associated with cancer recurrence. The purpose of this study was to examine how a 16-week therapeutic yoga program (TYP) modulates the cytokine profile in heterogeneous cancer survivors.

Methods: Eligible participants were 18 years of age or older and clinically diagnosed with cancer. Consenting participants were asked to attend three, 75-min sessions weekly of TYP with meditation. Seventeen patients provided blood samples at baseline and end of study. Eight cytokines (interferon (IFN)-γ; interleukin (IL)-1b, IL-1ra, IL-4, IL-6, IL-8, IL-10; and tumor necrosis factor (TNF)-α), three receptors (sIL-6R, sTNFRI, sTNFRII), and C-reactive protein (CRP) were quantified.

Results: Patients were 59.6 ± 7.3 years old; over half (56%) were overweight or obese BMI ≥ 25 kg/m2); majority were female (71%) and breast cancer survivors (65%), of which 44% were Hispanic. Marked reductions were observed in all cytokines except IL-4, with significant reductions (p < 0.05) found in IL-1b (- 13%) and IL-1ra (- 13%). No significant changes were observed in soluble cytokine receptors or CRP.

Conclusions: TYP led to significant reduction in circulating cytokines associated with chronic inflammation in a heterogeneous sample of cancer survivors.

Keywords: Body composition; Immunology; Physical activity; Recurrence; Survivorship.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • C-Reactive Protein / metabolism
  • Cancer Survivors*
  • Cytokines
  • Female
  • Humans
  • Inflammation
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-4
  • Male
  • Meditation*
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Tumor Necrosis Factor-alpha
  • Yoga*

Substances

  • Cytokines
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-4
  • Tumor Necrosis Factor-alpha
  • C-Reactive Protein